Compare RBBN & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBBN | KALA |
|---|---|---|
| Founded | 1997 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 382.8M | 319.6M |
| IPO Year | 2017 | 2017 |
| Metric | RBBN | KALA |
|---|---|---|
| Price | $2.81 | $0.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $4.67 | ★ $31.50 |
| AVG Volume (30 Days) | 769.4K | ★ 2.6M |
| Earning Date | 04-28-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 170.97 | 67.39 |
| EPS | ★ 0.22 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.97 | N/A |
| Revenue Next Year | $6.69 | N/A |
| P/E Ratio | $12.32 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.83 | $0.15 |
| 52 Week High | $4.29 | $20.58 |
| Indicator | RBBN | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 73.17 | 42.86 |
| Support Level | $2.69 | $0.15 |
| Resistance Level | $2.88 | $0.72 |
| Average True Range (ATR) | 0.12 | 0.02 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 97.47 | 62.84 |
Ribbon Communications Inc provides communications technology to service providers and enterprises, offering software and high-performance hardware products, network solutions, and services for secure data and voice communications, as well as high-bandwidth networking for residential and enterprise customers across industries such as finance, education, government, utilities, and transportation. It operates through two segments: Cloud and Edge, which generate maximum revenue and deliver software-centric, cloud-native solutions for VoIP, VoLTE, VoNR, and unified communications, and IP Optical Networks, which support growing telecommunications traffic from 5G, distributed cloud computing, and other applications. The Company generates the majority of its revenue from the United States.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.